Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 2093 • 2016 ACR/ARHP Annual Meeting
Association of Conventional Risk Factors and Antiphospholipid Antibodies to Thrombosis in Patients with Autoimmune Diseases: Lessons Learned from a Year-Long Systematic Assessment
Polona Žigon¹, Anuška Podovšovnik², Ales Ambrozic³, Matija Tomsic¹, Alojzija Hocevar¹, Natasa Gaspersic³, Ziga Rotar¹, Sonja Praprotnik⁴, Snezna Sodin Semrl^1,5 and Saša Čučnik^1,6, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Divison of Internal Medicine, General Hospital Izola, Izola, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, ⁴Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia, ⁵Faculty of Mathematics, Natural Science and Information Technology, University of Primorska, Koper, Slovenia, ⁶Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
Background/Purpose: Patients with autoimmune disorders are at risk for thrombotic events and antiphospholipid antibodies (aPL) are one of known markers of increased thrombotic risk. The…
Abstract Number: 2094 • 2016 ACR/ARHP Annual Meeting
Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System
Hiroyuki Nakamura¹, Kenji Oku², Ryo Hisada², Kazumasa Ohmura², Masaru Kato², Toshiyuki Bohgaki², Olga Amengual², Tetsuya Horita², Shinsuke Yasuda² and Tatsuya Atsumi², ¹Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Complement activation is proposed as one of the major thrombophilic mechanisms in antiphospholipid syndrome (APS). Among three complement pathways (classical, alternative and lectin), activation…
Abstract Number: 2097 • 2016 ACR/ARHP Annual Meeting
Cardiolipin-Producing Candidate Commensals in the Gut Microbiome of Antiphospholipid Syndrome Patients
Cassyanne L. Aguiar^1,2, William Ruff³, Andrew Goodman⁴, Doruk Erkan⁵ and Martin Kriegel^3,6, ¹Hospital for Special Surgery- NewYork-Presbyterian / Weill Cornell Medicine, New York, NY, ²Pediatric Rheumatology, Cohen Children's Medical Center / Hofstra Northwell School of Medicine, Lake Success, NY, ³Immunobiology, Yale School of Medicine, New Haven, CT, ⁴Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, ⁵Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁶Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: Pathogen-associated transient antiphospholipid antibodies suggest a microbial trigger for antiphospholipid syndrome (APS). We hypothesized that the gut microbiota could represent a chronic stimulus in…
Abstract Number: 2099 • 2016 ACR/ARHP Annual Meeting
Micrornas As Potential Modulators of Atherothrombosis in Antiphospholipid Syndrome
Patricia Ruiz-Limon¹, Maria Ángeles Aguirre Zamorano², Nuria Barbarroja², Yolanda Jiménez-Gómez², IVÁN ARIAS DE LA ROSA², Eduardo Collantes-Estévez², Pedro Segui², Francisco Velasco³, Rocio Gonzalez-Conejero⁴, Raul Teruel⁴, Constantino Martinez⁴, Maria Jose Cuadrado⁵, Carlos Perez-Sanchez² and Chary Lopez-Pedrera², ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Hematology, IMIBIC-Reina Sofia Hospital, Hematology Unit, Cordoba, Spain, ⁴Regional Centre for Blood Donation, University of Murcia, Murcia, Spain, ⁵St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: 1) To identify and characterize microRNAs linked to thrombosis and atherosclerosis development in APS; 2) To assess the effects of antiphospholipid antibodies in that…
Abstract Number: 2456 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results from a Multicenter Italian Cohort over 20 Years of Experience
Maria Grazia Lazzaroni¹, Laura Andreoli¹, Cecilia B. Chighizola², Teresa Del Ross³, Maria Gerosa⁴, Anna Kuzenko³, Maria Gabriella Raimondo⁴, Andrea Lojacono⁵, Sonia Zatti⁵, Francesca Ramazzotto⁵, Laura Trespidi⁶, Pier Luigi Meroni⁷, Vittorio Pengo³, Amelia Ruffatti³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, ³Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁴University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁵Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶L.Mangiagalli Obstetric Clinic, IRCSS Cà Granda, Ospedale Maggiore of Milano, Milano, Italy, ⁷Hospital G.Pini, University of Milano, IRCSS Instute Auxologico Italiano, Milano, Italy
Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results From a Multicenter Italian Cohort Over 20 Years Of Experience Background/Purpose: Antiphospholipid antibodies (aPL)…
Abstract Number: 2457 • 2016 ACR/ARHP Annual Meeting
Role of Hydroxychloroquine in Improving Pregnancy Outcomes in Women with Antiphospholipid Antibodies without Other Underlying Connective Tissue Disease
Savino Sciascia¹, Simone Baldovino², Dario Roccatello² and Maria Jose Cuadrado³, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ³St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: Heparins and/or low-dose aspirin represent the treatment of choice for the management of pregnant women with antiphospholipid antibodies (aPL). However, despite these treatments, maternal, fetal, and…
Abstract Number: 2201 • 2015 ACR/ARHP Annual Meeting
Triple Positivity of Antiphospholipid Antibody As the Main Thrombotic Factor in a Long-Term Follow-up Study of 98 Asymptomatic Apl-Positive Carriers
Cécile Yelnik^1,2, Elodie Drumez³, Sylvain Dubucquoi^2,4,5, Vincent Sobanski^1,2,4, Hélène Maillard^1,6, Alain Duhamel³, David Launay^1,2,4, Eric Hachulla^1,2,4, Pierre-Yves Hatron^1,2 and Marc Lambert^1,2,4, ¹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ²Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ³CERIM, Université Lille Nord de France, Lille, France, ⁴LIRIC, INSERM UMR 995, Lille, France, ⁵Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, ⁶Faculté de Médecine Henri Warembourg, Université Lille Nord de France, lille, France
Background/Purpose: There is limited data regarding the long-term risk of developing a first-time thrombotic event and prophylactic benefits of aspirin use in asymptomatic aPL-positive carriers.…
Abstract Number: 1752 • 2015 ACR/ARHP Annual Meeting
Characterization of Epitopes Identified with Cerebral Vasculature Injury
Melissa Butts¹, Jess Edison¹, Christopher Tracy¹, Brian Stout¹, Huazhen Chen² and Chantal Moratz², ¹Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ²Medicine, Uniformed Services University School of Health Sciences, Bethesda, MD
Background/Purpose: There is an association between natural antibodies, such as anti-phospholipid antibodies, and vasculature injury in stroke and in SLE models of systemic ischemic damage. …
Abstract Number: 1996 • 2015 ACR/ARHP Annual Meeting
Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies
Jane E. Salmon^1,2, Mimi Kim³, Marta Guerra⁴, Elianna Kaplowitz¹, Carl Laskin⁵, Michelle Petri⁶, Ware D. Branch^7,8, Michael Lockshin⁹, Lisa R. Sammaritano², Joan T. Merrill¹⁰, Mary D. Stephenson¹¹, Munther Khamashta¹², Alan M. Peaceman¹³, Anne Lynch¹⁴ and Jill P. Buyon¹⁵, ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁴Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁵Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷University of Utah, Salt Lake City, UT, ⁸Intermountain Healthcare, Salt Lake City, UT, ⁹Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹University of Illinois College of Medicine, Chicago, IL, ¹²Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ¹³Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁴Colorado School of Public Health, Aurora, CO, ¹⁵NYU School of Medicine, New York, NY
Background/Purpose: Women with SLE and/or aPL antibodies (SLE/APL) are at increased risk for adverse pregnancy outcomes (APO) yet identification of those destined for complications remains…
Abstract Number: 2001 • 2015 ACR/ARHP Annual Meeting
Reduction of HLA Class II Expression and Beta-2-Glycoprotein I Presentation By Fluvastatin in Vitro and in Vivo: Possible Mechanism of Statin-Induced-Deprocoagulation in the Antiphospholipid Syndrome
Toshiyuki Watanabe^1,2, Kenji Oku¹, Olga Amengual¹, Ryo Hisada¹, Kazumasa Ohmura¹, Haruki Shida¹, Yuka Shimizu¹, Masaru Kato¹, Toshiyuki Bohgaki¹, Tetsuya Horita¹, Shinsuke Yasuda¹, Akihiro Ishizu³, Hisashi Arase⁴ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²3rd Department of Internal medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan, ³Faculty of Health Sciences, Hokkaido University, Sapporo, Japan, ⁴Laboratory of Immunochemistry, WPI Immunology Frontier Research Center, Osaka University, Suita, Japan
Background/Purpose: Human leukocyte antigen (HLA)-DRB1*07:01 is one of the susceptibility alleles for antiphospholipid syndrome (APS). Recently we have reported that beta-2-glycoprotein I (b2GPI) /HLA class…
Abstract Number: 2180 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors
Maria Gerosa^1,2, Paola Adele Lonati³, Tania Ubiali¹, Martina Cornalba¹, Maria Orietta Borghi^1,4 and Pier Luigi Meroni^1,2,5, ¹Department of Clinical Sciences and Community Health, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ²Division of Rheumatology, Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy, ³Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Jamaica, ⁴Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁵Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients display high levels of the cell-bound complement activation factor C4d deposits on erythrocytes, B lymphocytes and platelets. In particular,…
Abstract Number: 2182 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Livedo Reticularis Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Ersilia M. DeFilippis¹, Denis Wahl² and Stephane Zuily², ¹Department of Medicine, Brigham and Women's Hospital, Boston, MA, ²CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France
Background/Purpose : Livedo reticularis (LR) is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our…
Abstract Number: 2185 • 2015 ACR/ARHP Annual Meeting
Small but Clinically Insignificant Decreases in Antiphospholipid Antibody Titers Occur in aPL-Positive Patients during Pregnancy
Cécile Yelnik^1,2, Flint Porter^3,4, Ware D. Branch^3,4, Jill P. Buyon⁵, Marta Guerra⁶, Carl Laskin⁷, Michael Lockshin⁸, Michelle Petri⁹, Joan T. Merrill¹⁰, Lisa R. Sammaritano¹¹, Mary D. Stephenson¹², Mimi Y. Kim¹³ and Jane E. Salmon^11,14, ¹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ²Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ³University of Utah, Salt Lake City, UT, ⁴Intermountain Healthcare, Salt Lake City, UT, ⁵NYU School of Medicine, New York, NY, ⁶Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁷Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁸Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, ⁹Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²University of Illinois College of Medicine, Chicago, IL, ¹³Albert Einstein College of Medicine, Bronx, NY, ¹⁴Hospital for Special Surgery, New York, NY
Background/Purpose: The presence of aPL has been associated with pregnancy complications, but the evolution of aPL titers during pregnancy in aPL-positive patients and the utility…
Abstract Number: 2186 • 2015 ACR/ARHP Annual Meeting
The Role of Hydroxychloroquine Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies
Savino Sciascia¹, Beverely J Hunt², Eva Talavera-Garcia³, Gloria Lliso³, Munther Khamashta³ and Mª Jose Cuadrado⁴, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Thrombosis & Haemostasis, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, London, United Kingdom, ³Louise Coote Lupus Unit, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
Background/Purpose: With good management, around 70% of pregnant women with Antiphospholipid Syndrome (APS) will deliver a viable live infant.However, current management does not prevent all…
Abstract Number: 2187 • 2015 ACR/ARHP Annual Meeting
Anti-Phosholipid Antibodies and Female Infertility: A Systematic Revision of Literature
Cecilia B. Chighizola¹, Guilherme Ramires de Jesus² and W. David Branch³, ¹Department of Clinical Sciences and Community Health, University of Milan, Istituto Auxologico Italiano, Cusano Milanino, Italy, ²Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT
Background/Purpose: Infertility is a common condition, affecting 8-12% of couples in childbearing age. Even though the association of aPL with infertility is highly debated, infertile…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].